Surety Medicine

 Surety Medicine

Last Updated: December 20, 2020

​Surety medicine focuses on protecting the health of the personnel who deal with nuclear, biological or chemical materials, and on medical requirement compliance to help ensure the security of the materials and the work force.

 
January 2021 Surety Medicine Teleconference

SYNCOPAL EPISODES AND THEIR IMPACT ON RELIABILITY FOR PERSONNEL RELIABILITY PROGRAMS

Wednesday, 20 January 2021 will bring the next monthly Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for January is “Syncopal Episodes and Their Impact on Reliability in the PRP.”  Presenting will be Army Public Health Center’s senior surety medicine occupational health physician.  

The teleconference will be hosted on the web and by phone on Defense Collaboration Services (DCS).

To request additional information, email the Army Public Health Center Surety Medicine Program at:
usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil.
___________________________________________________________

FY2021 SURETY MEDICINE TELECONFERENCE SCHEDULE

All teleconference begin at 1300 / 1 p.m. Eastern Time.  Subject to Change.

Presentation Title

Date




Syncopal Conditions and Impact on Reliability for PRP
                        1/20/2021
The Diagnosis, Evaluation and Treatment of Laboratory-Acquired Anthrax Infections
                        2/17/2021
Updates on Patient Decontamination and the Use of RSDL
                        3/17/2021
Peripheral Vascular Disease, DVT, and Anticoagulation— Assessing        PRP Suitability
                        4/21/2021
Screening for Dementia and Cognitive Impairments: PRP Suitability and Reliability Issues
                        5/19/2021
Updates on the Treatment of Diabetes Mellitus:
PRP Implications
                        6/16/2021
The COVID-19 Pandemic: Lessons Learned on Diagnosis, Treatment, and Return to PRP Duties
                        7/21/2021
Oncology and the PRP:  What Every CMA Should Know
                        8/18/2021
BPRP, BSAT and The Responsible Official
    9/15/2021


--ALERT--

 NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote(R) combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labeled expiration dates, some are now extended to 2022. 

DuoDote(R) lots which expired or will soon expire in 2020 include:  0AE792 and 1AE200 (expires 31 December 2020).  Lots expiring in 2021 include:  1AE201, 1AE406, 1AE502, 1AE515, 1AE516, 1AE701, 1AE702, and 1AE703. 

Complete FDA information related to the auto-injector shelf life extension program can be found at this  FDA Drug Safety Page.External Link

Information on this page also includes the latest updates on shelf life extensions for the AtroPen(R) (atropine), CANA (diazepam), morphine sulfate, and pralidoxime chloride auto-injectors, with dates listed.